Tetec AG
10
0
2
7
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
10.0%
1 terminated/withdrawn out of 10 trials
87.5%
+1.0% vs industry average
20%
2 trials in Phase 3/4
0%
0 of 7 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (10)
Non-interventional Study in Pediatric Patients Treated With NOVOCART Inject in the Knee
Role: lead
Peptide-coupled Red Blood Cells for the Treatment of Multiple Sclerosis
Role: collaborator
Non-interventional Study With NOVOCART® 3D for the Treatment of Cartilage Defects of the Knee in Pediatric Patients
Role: lead
NOVOCART® Inject Plus for Cartilage Defects of the Knee
Role: lead
Phase III Study to Evaluate Safety and Effectiveness of NOVOCART 3D Plus vs. Microfracture in Knee Cartilage Defects
Role: lead
Safety and Efficacy With NOVOCART® Disc Plus (ADCT) for the Treatment of Degenerative Disc Disease in Lumbar Spine
Role: lead
Non-interventional Study With NOVOCART® Basic in Patients Treated for Cartilage Defects in the Knee With MAC
Role: lead
Observational Study With NOVOCART® Inject in the Reconstruction of the Hip Joint With Full Thickness Cartilage Defects
Role: lead
Non-Interventional Study to Evaluate Safety and Efficacy of NOVOCART 3D in Patients With Cartilage Defects
Role: lead
Non-interventional Study With NOVOCART® Inject in the Reconstruction of the Knee Cartilage Defects
Role: lead
All 10 trials loaded